What the Oregon Primate Study Found

Researchers at Oregon Health & Science University tested whether a three-part treatment could remove an HIV-like virus from newborn macaques if started within days of exposure. The animals received daily antiretroviral therapy for 27 weeks, a single dose of two broadly neutralizing antibodies, and nine weekly doses of leronlimab, an experimental monoclonal antibody. All eight animals in the final combination group had detectable virus in their blood when treatment began.

After treatment stopped, the virus did not return. During six months of follow-up, the researchers found no viral DNA in the animals’ blood. They then deliberately depleted CD8 T cells—an immune cell population that can keep virus hidden or controlled—to check whether the virus was truly gone rather than merely held in check. No viral rebound occurred, and at 84 weeks after exposure tissue samples still showed no detectable SHIV, the simian-human immunodeficiency virus used in the study.

The contrast with earlier groups was sharp. When the researchers tested ART alone or two-drug combinations, virus levels fell but later came back after treatment ended. The full three-part combination was the only approach in which the virus stayed undetectable across all eight animals.

The study is preclinical: it was conducted in monkeys, not human babies. The authors and outside experts caution that the findings do not yet establish a cure for HIV in human newborns, but they point to a possible strategy for clearing infection when treatment begins very early.

Why the Three-Part Macaque Result Is Promising—and Hard to Translate

Why ART Alone Leaves a Reservoir

Antiretroviral therapy suppresses HIV replication but does not remove the virus from every cell. The problem is the reservoir: infected cells in which the virus remains silent and can reactivate if treatment stops. In this study, ART alone and ART paired with broadly neutralizing antibodies lowered SHIV levels, but the virus eventually returned—consistent with earlier research the authors cited.

What the Three-Part Regimen Did Differently

The triple combination attacks early infection from different directions. ART blocks viral replication, broadly neutralizing antibodies target the virus itself, and leronlimab adds a third experimental monoclonal antibody mechanism. Jagdish Khubchandani, a public health professor at New Mexico State University who was not involved in the study, called the approach “multipronged” and said targeting different stages of early infection “makes a lot of biological sense.” The result—no rebound even after CD8 T-cell depletion—is a meaningful piece of evidence that the virus was eliminated rather than simply suppressed.

Still, the success was limited to a narrow window. Treatment began 72 hours after exposure, when the virus was already detectable in blood. The researchers and commentators explicitly note that they do not yet know whether starting later would work, or at what dose and with what safety profile in human infants. Those are not minor caveats; they define the next stage of research.

What Stands Between Eight Macaques and Human Newborns

Jagmohan Batra, a pediatric infectious disease specialist at Miller Children’s and Women’s Hospital Long Beach and medical director of its Bickerstaff Family Center, called the findings “very important” but highlighted a practical problem: clinicians would need to identify babies who acquired HIV very early. He added that an approach like this might initially be most useful for babies at high risk of acquiring HIV during delivery, while clinicians await birth test results. In human newborns, infection acquired before or during delivery may already be established longer than the 72-hour window, which could mean more reservoirs in more tissues.

The study therefore sits at the boundary between encouraging proof of concept and unresolved clinical translation. It is a candidate regimen, not a treatment recommendation.

What the Findings Do and Do Not Change for Newborn HIV

  • For clinicians: This does not change newborn HIV protocols today. The result comes from eight infant macaques, and the authors do not claim evidence in human infants.
  • For researchers and funders: The specific regimen—one dose of two broadly neutralizing antibodies, nine weekly leronlimab doses, and 27 weeks of daily ART started at 72 hours—is the candidate protocol that would need to be tested for dosing, safety, later timing and efficacy in human newborns.
  • For public health programs in high-burden settings: The most plausible near-term relevance is for babies at high risk of acquiring HIV around delivery, as Dr. Batra noted, not for people with established adult infection.
  • For patients and families: The study offers hope but no immediate change; current prevention of mother-to-child transmission remains the effective standard while the necessary human research proceeds.